LS60 Stock Overview
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Clinical Laserthermia Systems AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr1.34 |
52 Week High | kr24.40 |
52 Week Low | kr0.04 |
Beta | 0.48 |
1 Month Change | 252.37% |
3 Month Change | 67.38% |
1 Year Change | -91.44% |
3 Year Change | -98.08% |
5 Year Change | -99.22% |
Change since IPO | -99.16% |
Recent News & Updates
Recent updates
Shareholder Returns
LS60 | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | -13.2% | -1.9% | -1.0% |
1Y | -91.4% | -10.8% | 2.0% |
Return vs Industry: LS60 underperformed the German Medical Equipment industry which returned -10.8% over the past year.
Return vs Market: LS60 underperformed the German Market which returned 2% over the past year.
Price Volatility
LS60 volatility | |
---|---|
LS60 Average Weekly Movement | 368.6% |
Medical Equipment Industry Average Movement | 4.5% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LS60's share price has been volatile over the past 3 months.
Volatility Over Time: LS60's weekly volatility has decreased from 1671% to 369% over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 14 | Dan Mogren | www.clinicallaser.se |
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment.
Clinical Laserthermia Systems AB (publ) Fundamentals Summary
LS60 fundamental statistics | |
---|---|
Market cap | €10.96m |
Earnings (TTM) | -€6.85m |
Revenue (TTM) | €710.53k |
15.4x
P/S Ratio-1.6x
P/E RatioIs LS60 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LS60 income statement (TTM) | |
---|---|
Revenue | kr8.27m |
Cost of Revenue | kr5.28m |
Gross Profit | kr3.00m |
Other Expenses | kr82.79m |
Earnings | -kr79.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 17, 2024
Earnings per share (EPS) | -10.16 |
Gross Margin | 36.23% |
Net Profit Margin | -964.49% |
Debt/Equity Ratio | 0% |
How did LS60 perform over the long term?
See historical performance and comparison